Search Press releases Keywords From To 28 Feb 2024 UCB on Growth Path for a Decade Plus Read More 9 Feb 2024 Latest analyses of bimekizumab phase 3 studies in moderate to severe hidradenitis suppurativa to be presented at EHSF 2024 Read More 6 Feb 2024 Transparency notification FMR LLC Read More 8 Jan 2024 UCB announces European Commission approval of RYSTIGGO[®]▼ (rozanolixizumab) for the treatment of adults with generalized myasthenia gravis in Europe Read More 27 Dec 2023 BIMZELX® (bimekizumab) Receives Approval in Japan for the Treatment of Psoriatic Arthritis, Non-radiographic Axial Spondyloarthritis and Ankylosing Spondylitis Read More 4 Dec 2023 UCB announces European Commission approval of ZILBRYSQ[®]▼ (zilucoplan) for the treatment of adults with generalized Myasthenia Gravis Read More Pagination First page Previous page Previous … Page 18 Page 19 Page 20 Page 21 Current page 22 Page 23 Page 24 Page 25 Page 26 … Page 22 of 70 Next page Next Last page Stay up-to-date on the latest news and information from UCB Subscribe
